Our proprietary market analysis suggests predictions for Icon Energy 's price over the next three months point to a drop. ICON stock is expected to peak at $2.93 on Jan 19, 2026 before potentially ...
Summary • Biohaven Ltd. shares dropped 16.6% to $9.02 in after-hours trading following a Phase 2 study update on BHV-7000 for major depressive disorder.• The clinical update revealed challenges ...
Summary • Elong Power Holding Limited’s stock fell 8.6% in after-hours trading to $0.1305 following a close at $0.1427.• The company announced a 16-for-1 reverse stock split during a special ...
Summary • SOBR Safe, Inc. shares fell 17% in after-hours trading to $1.96 following a $2 million private placement announcement.• The company plans to issue 1,290,324 shares at $1.55 per share, which ...
Summary • Nuvve Holding Corp. shares rose 5.6% in after-hours trading following a strategic agreement.• The company signed a non-binding MOU with E&B Renewables to deploy Battery Energy Storage ...
Summary • Webus International Limited (WETO) fell 7.5% to $0.90 in after-hours trading despite announcing expansion into the U.S. outdoor smart equipment and robotics market.• The stock’s trading ...
Costco Wholesale Corporation (COST) has recently garnered attention in the investment community after Chuck Cerankosky of Northcoast Research upgraded the stock to a “Buy” o. With a current trading ...
Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• Yartemlea is the first therapy targeting hematopoietic stem cell ...
Summary • Lexaria Bioscience Corp. (LEXX) shares fell 9.1% to $0.5633 despite recent successful clinical study results.• The company reported a significant reduction in side effects from its Phase 1b ...
Summary • Rezolute, Inc. shares rose 13.6% to $2.75 amidst ongoing investigations and legal concerns following a significant trial failure.• The stock has seen increased trading volume, with a notable ...
Summary • SRx Health Solutions Inc. shares rose 16.5% to $0.2561 amid investor interest, despite the absence of a clear catalyst for the price increase.• The company expanded its risk-intelligence ...
Summary • Can-Fite BioPharma shares fell 19.9% to $0.1926 following a reverse stock split announcement.• The company will implement a 1-for-3,000 reverse split effective January 2, 2026, approved by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback